NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April 1, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
STRO-002, Sutro’s second clinical program, is designed to deliver “toxic payloads” to kill cancer cells Sutro plans to enroll up to 160 patients in open-label, multicenter study SOUTH SAN FRANCISCO, Calif., March 15, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today...
Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott...
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the appointment of Andreas Maderna, Ph.D., as vice president of chemistry. Dr. Maderna has extensive...
Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at...
Sutro Achieves $10 Million Milestone Payment from Celgene
Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company earned $10 million in a...
Sutro Biopharma Reports Third Quarter 2018 Financial Results
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif., Nov. 13, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the U.S. Food and Drug...
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical...
Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018-- Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001 for the treatment of...
